{"id":"poma","rwe":[{"pmid":"41908829","year":"2026","title":"PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike-ACE2 interaction and protecting lung tissue.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"41849761","year":"2026","title":"Effects of Wearable Devices on Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Within the International Classification of Functioning, Disability, and Health Framework.","finding":"","journal":"Journal of medical Internet research","studyType":"Clinical Study"},{"pmid":"41827579","year":"2026","title":"Visuo-Vestibular Virtual Reality-Based Training for People with Stroke: A Feasibility Study.","finding":"","journal":"Healthcare (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41734338","year":"2026","title":"Implementation of a Personalized Medicine Approach in Patients With Type 2 Diabetes Mellitus Receiving Multiple Daily Insulin Injections (POMA Project): Protocol for a Before-and-After Intervention Study.","finding":"","journal":"JMIR research protocols","studyType":"Clinical Study"},{"pmid":"41703240","year":"2026","title":"Association between backward walking speed and physical balance and fall risk in community-dwelling older adults.","finding":"","journal":"GeroScience","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Bristol","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Dose interruption due to adverse reactions","drugRate":"67%","severity":"common","organSystem":""},{"effect":"Dose reduction due to adverse reactions","drugRate":"42%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Discontinuation due to adverse reactions","drugRate":"11%","severity":"serious"},{"effect":"Serious adverse reactions (KS patients)","drugRate":"18%","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Atrial fibrillation","drugRate":"","severity":"serious"},{"effect":"Cardiac failure congestive","drugRate":"","severity":"serious"},{"effect":"Pulmonary embolism","drugRate":"","severity":"serious"},{"effect":"Respiratory failure","drugRate":"","severity":"serious"},{"effect":"Septic shock","drugRate":"","severity":"serious"},{"effect":"Neutropenic sepsis","drugRate":"","severity":"serious"},{"effect":"Interstitial lung disease","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Pomaglumetad"],"company":"Bristol","patents":[{"applNo":"N204026","source":"FDA Orange Book","status":"Active","expires":"Jun 21, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8828427","drugSubstance":true},{"applNo":"N204026","source":"FDA Orange Book","status":"Active","expires":"May 19, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10555939","drugSubstance":false},{"applNo":"N204026","source":"FDA Orange Book","status":"Active","expires":"May 19, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9993467","drugSubstance":false},{"applNo":"N204026","source":"FDA Orange Book","status":"Active","expires":"Dec 21, 2031","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8828427*PED","drugSubstance":false},{"applNo":"N204026","source":"FDA Orange Book","status":"Active","expires":"Nov 19, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9993467*PED","drugSubstance":false},{"applNo":"N204026","source":"FDA Orange Book","status":"Active","expires":"Nov 19, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10555939*PED","drugSubstance":false}],"pricing":[],"allNames":["poma"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from New York State Psychiatric Institute to Bristol"},{"date":"2022-01-26","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"},{"date":"2027-05-14","type":"negative","source":"FDA Orange Book","milestone":"ODE-296 exclusivity expires"},{"date":"2027-11-14","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"},{"date":"2031-06-21","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8828427 expires"}],"approvals":[],"ecosystem":[],"mechanism":{"target":"Protein cereblon, Cereblon isoform 4","modality":"Small Molecule","explanation":"Imagine Poma as a key that fits into a lock in our cells. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This process is complex and involves many different molecules and cellular pathways.","oneSentence":"Poma is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.","technicalDetail":"Poma's exact mechanism of action is unknown, but it is believed to involve the modulation of a specific biological pathway or target, potentially through competitive inhibition or allosteric modulation."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=poma","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=poma","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:27:29.925771","biosimilars":[],"competitors":[],"exclusivity":[{"code":"ODE-296","date":"May 14, 2027"},{"code":"ODE-297","date":"May 14, 2027"},{"code":"ODE-296","date":"May 14, 2027"},{"code":"ODE-297","date":"May 14, 2027"},{"code":"ODE-296","date":"May 14, 2027"},{"code":"ODE-297","date":"May 14, 2027"},{"code":"ODE-296","date":"May 14, 2027"},{"code":"ODE-297","date":"May 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"},{"code":"PED","date":"Nov 14, 2027"}],"genericName":"poma","indications":{"approved":[{"name":"Multiple myeloma","diseaseId":"multiple-myeloma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bristol","drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07468110","phase":"","title":"Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke","status":"RECRUITING","sponsor":"Marmara University","startDate":"2026-03-10","conditions":["Chronic Stroke","CONUT Score","Balance Assessment","Functional Status"],"enrollment":47,"completionDate":"2027-03-10"},{"nctId":"NCT05665673","phase":"","title":"Relation of Functional ındependence to Balance, Exercise Capacity, and Peripheral Muscle Strength","status":"COMPLETED","sponsor":"Istinye University","startDate":"2022-12-19","conditions":["Functional Independence","Balance; Distorted","Exercise Capacity","Peripheral Muscle Strength"],"enrollment":52,"completionDate":"2023-07-01"},{"nctId":"NCT05102435","phase":"","title":"Translation and Validation of the Performance Oriented Mobility Assessment (Poma) Scale Into Urdu Version","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2021-11-01","conditions":["Fall"],"enrollment":300,"completionDate":"2022-03-31"},{"nctId":"NCT05203094","phase":"","title":"Urdu Version of Tinetti Balance and Gait Assessment Scale,(POMA),Reliability and Validity Study","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2021-03-30","conditions":["Balance; Distorted"],"enrollment":100,"completionDate":"2022-02-15"},{"nctId":"NCT03321617","phase":"PHASE1","title":"Glutamate Reducing Interventions in Schizophrenia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2018-04-17","conditions":["Clinical High Risk for Psychosis"],"enrollment":16,"completionDate":"2020-03-13"},{"nctId":"NCT04479774","phase":"NA","title":"Effects of Compelled Body Weight Shift Technique for Rehabilitation of Individuals With Chronic Stroke","status":"COMPLETED","sponsor":"Northwest Institute of Health Sciences, Pakistan","startDate":"2020-07-12","conditions":["Chronic Stroke"],"enrollment":27,"completionDate":"2020-08-31"},{"nctId":"NCT02919774","phase":"PHASE1","title":"Pomaglumetad Effects on Glutamate Biomarkers","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2016-10","conditions":["Healthy Controls"],"enrollment":95,"completionDate":"2018-05-25"},{"nctId":"NCT01979276","phase":"PHASE1,PHASE2","title":"Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-11","conditions":["Multiple Myeloma"],"enrollment":4,"completionDate":"2016-10"},{"nctId":"NCT03376490","phase":"","title":"Study of the Association of Muscle Strength, Balance and Other Factors With Vitamin Levels Among Elderly Diabetics","status":"COMPLETED","sponsor":"SingHealth Polyclinics","startDate":"2012-01-01","conditions":["Muscle Strength","Vitamin B 12 Deficiency","Folate Deficiency","Vitamin D Deficiency","Hyperhomocysteinemia","Fall"],"enrollment":56,"completionDate":"2014-08-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"New York State Psychiatric Institute","relationship":"Original Developer"},{"period":"present","companyName":"Bristol","relationship":"Current Owner"}],"publicationCount":420,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-03-31 10:31:17.104625+00","biosimilarFilings":[],"originalDeveloper":"New York State Psychiatric Institute","recentPublications":[{"date":"2026","pmid":"41908829","title":"PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike-ACE2 interaction and protecting lung tissue.","journal":"Frontiers in pharmacology"},{"date":"2026 Mar 18","pmid":"41849761","title":"Effects of Wearable Devices on Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Within the International Classification of Functioning, Disability, and Health Framework.","journal":"Journal of medical Internet research"},{"date":"2026 Mar 2","pmid":"41827579","title":"Visuo-Vestibular Virtual Reality-Based Training for People with Stroke: A Feasibility Study.","journal":"Healthcare (Basel, Switzerland)"},{"date":"2026 Feb 24","pmid":"41734338","title":"Implementation of a Personalized Medicine Approach in Patients With Type 2 Diabetes Mellitus Receiving Multiple Daily Insulin Injections (POMA Project): Protocol for a Before-and-After Intervention Study.","journal":"JMIR research protocols"},{"date":"2026 Feb 17","pmid":"41703240","title":"Association between backward walking speed and physical balance and fall risk in community-dwelling older adults.","journal":"GeroScience"}],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Apotex","Breckenridge","Eugia Pharma","Hetero Labs Ltd V","Mylan","Teva Pharms Usa"],"status":"active","brandName":"POMA","companyName":"Bristol","companyId":"bristol","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Poma is a small molecule drug developed by the New York State Psychiatric Institute, currently owned by Bristol. However, due to the lack of available information, its target, drug class, and approved indications are unknown. Poma is available as a generic medication, with six generic manufacturers, but its commercial status as patented or off-patent is unclear. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand Poma's characteristics and clinical applications.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}